Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Affini-T Therapeutics

Main (gene editing) focus: Next-generation cell therapies

Company stage: Pre-clinical

Diseases: Solid tumours

Genome editing tool: CRISPR

Funding stage: Private

Location: Boston, MA, USA



Partners: Metagenomi

Affini-T Therapeutics is focused on developing pioneering engineered T cell receptor (TCR) T cell therapies. The company's involvement in the gene-editing space comes through its partnership with Metagenomi, although lead programmes have yet to be announced as well as the specifics regarding the gene-editing system in use.


HashtagAffini-T Therapeutics

Company: Affini-T Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine